Browse studies

Find your next paid study

3,843 recruiting studies matching your filters

A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) …

Metastatic Non-small Cell Lung Cancer With MTAP Deletion

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT07063745

Phase 1

A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with …

Lung CancerBreast Cancer

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT06618287

Phase 2

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and p…

Non-small Cell Lung Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT05061550

Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)

Investigators seek to determine the sensitivity and specificity of a combined HPV 16 DNA and host gene methylation oral biomarker panel to distinguish early Or…

Oropharyngeal CancerHPV-Related Carcinoma

Estimated

~$10 – $750

H. Lee Moffitt Cancer Center and Research InstituteNCT06305676

Phase 2

Obesity Treatment Using Phentermine-Topiramate ER to Improve Metabolic Health in Adolescents and Young Adults Surviving Leukemia and Lymphoma

This study is evaluating whether a weight-loss medication (PHEN/TOP) combined with healthy lifestyle counseling is safe, well tolerated, and can help reduce ob…

Acute Lymphoblastic Leukemia in RemissionHodgkin Lymphoma in RemissionNon-Hodgkin Lymphoma in Remission+1 more

Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT07790913

Phase 1

A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination With Cetuximab and Encorafenib in Patients With Refractory BRAF V600E Metastatic Colorectal Cancer

This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encorafenib in treating patients with colorect…

Metastatic Colorectal AdenocarcinomaRecurrent Colorectal AdenocarcinomaRefractory Colorectal Adenocarcinoma+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06102902

Phase 1

A Phase 1 Study of AWT020 in Patients With Advanced Solid Tumors

This study is aimed at establishing the MTD and/or the RP2D for AWT020 monotherapy and to provide safety, tolerability, efficacy, PK, immunogenicity characteri…

Advanced Cancers (Solid Tumors)

Estimated

~$10 – $8,750

Anwita BiosciencesNCT07822919

Phase 2

A Phase 2, Single-arm Study of Cadonilimab and FLOT Chemotherapy in Patients With Locally Advanced, Resectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

The purpose of this study is to find out whether adding cadonilimab to the usual chemotherapy approach is an effective and safe treatment for participants with…

Gastric CancerGastroesophageal-junction Cancer

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07631000

Observational

Accelerated Partial Breast Radiotherapy Study of a Personalized Holder for Prone Breast Immobilization to Enhance Local Delivery

The goal of this clinical trial is to find out whether using a personalized breast holder (called VENUS SHELL™) can improve positioning and patient comfort dur…

Invasive Breast Cancer Early StagesDuctal Carcinoma In Situ, DCIS

Estimated

~$10 – $7,500

HeroSupport SANCT07711847

Observational

Remotely-Delivered Cognitive Behavioral Stress Management Effects on Cancer Accelerated Aging in Older, Distressed Breast Cancer Survivors

The purpose of this research study to find out if a program called Remotely-delivered Cognitive Behavioral Stress Management (R-CBSM) can help women with breas…

Breast Cancer

Estimated

~$10 – $6,250

University of MiamiNCT07502352

Phase 3

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in partici…

Non-small Cell Lung Cancer

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT06561386

Phase 3

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more

Estimated

~$10 – $8,750

Revolution Medicines, Inc.NCT07252232